Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Neoplasms 3Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Cervical Neoplasms 1Sarcoma 1Kidney Neoplasms 1Endocrine Gland Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Vincristine 16Cyclophosphamide 16Filgrastim 13Etoposide 12Doxorubicin 12Radiotherapy 11Carboplatin 10X-Rays 9Dactinomycin 9Specimen Handling 8Phantoms, Imaging 8Magnetic Resonance Spectroscopy 8Granulocyte Colony-Stimulating Factor 8Temozolomide 6Melphalan 6Ifosfamide 6Topotecan 5Polymerase Chain Reaction 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Irinotecan 5Busulfan 5Biopsy 5sargramostim 4Stem Cell Transplantation 4Gene Expression Profiling 4Amplified Fragment Length Polymorphism Analysis 4Thiotepa 3Reverse Transcriptase Polymerase Chain Reaction 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × tariquidar × Clear all
NCT00011414 2019-07-16

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
29 enrolled
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡